Introduction
The ERK MAP kinase signal transduction pathway is induced by diverse mitogenic signals in many cell types, and a variety of evidence indicates that ERK activation is essential for cell cycle re-entry from quiescence (Brunet et al., 1999; Pages et al., 1993) . In addition, ERK is thought to be an important downstream mediator of the mitogenic and transforming effects of signalling oncogenes, such as Ras and Raf, which are themselves components of the ERK pathway (Cowley et al., 1994) . The relationship between ERK activity and cell proliferation is however complex; prolonged ERK activation can also promote terminal differentiation in some cell types (Cowley et al., 1994; Marshall, 1995) , whilst in others excessively intense or chronic ERK activation elicited by activated Ras or Raf oncogenes can lead to growth arrest or premature senescence via upregulation of the p21CIP1 cyclin-dependent kinase (cdk) inhibitor and other mechanisms (Sewing et al., 1997; Woods et al., 1997; Zhu et al., 1998) .
The viral Jun oncoprotein (v-Jun) encoded by ASV17 is a mutant form of the c-Jun component of the generic cellular transcription factor AP-1 (Vogt, 2001) . It is generally believed that v-Jun induces cell transformation in vitro and oncogenesis in vivo via misregulation of cellular target genes, however the nature of these genes remains ill defined. Although a number of proven or putative v-Jun target genes have been identified in recent years (Vogt, 2001) , in many cases the physiological relevance of their products for cell transformation or oncogenesis remains to be established.
In a complementary approach, we have sought to define the phenotype of cell transformation induced by v-Jun with a view to identifying specific physiological or biochemical processes whose perturbation may contribute to oncogenesis. We have pursued this analysis using primary chick embryo fibroblasts (CEFs), the presumed natural target cell for oncogenic conversion by v-Jun. One prominent consequence of cell transformation by v-Jun in this system is loss of normal cell cycle control. Specifically, v-Jun-transformed cells acquire the ability to divide in the absence of serum growth factors which normal, untransformed CEF require for proliferation . Furthermore, growth factorindependent cell cycle progression of v-Jun-transformed CEF is associated with the persistence of Retinoblastoma (Rb) protein phosphorylation and expression of cyclin A, cdk2, and cdc2, biochemical processes which in normal, untransformed CEF are wholly dependent on exposure to serum Clark and Gillespie, 1997) . Taken together, these observations indicate that v-Jun induces alterations in cell physiology which enable cells to sustain something closely resembling normal cell cycle progression in the absence of exogenous mitogenic stimulation. Although the underlying mechanism(s) is not yet fully understood, such a major deregulation of normal growth control is likely to be crucial for oncogenesis by v-Jun.
Clearly one potential explanation for this loss of mitogen dependence would be if v-Jun caused cells to synthesize mitogenic factors which substitute for serum and stimulate cell cycle progression via an autocrine mechanism. Similar autocrine loops are thought to contribute to the mitogenic effects of other oncogenes such as Ras (Treinies et al., 1999) and Raf (McCarthy et al., 1995) . Furthermore, a candidate autocrine factor, heparin-binding epidermal growth factor (HB-EGF), has recently been shown to be upregulated in vJun-transformed cells (Fu et al., 1999) . Interestingly, the gene encoding HB-EGF appears to be a direct target of v-Jun, and ectopic expression of HB-EGF in normal CEF disturbs growth control (Fu et al., 1999) , suggesting that increased expression of this factor is indeed likely to contribute to the phenotype of cell transformation induced by v-Jun.
We reasoned that if v-Jun were to promote cell cycle progression via an autocrine mechanism involving HB-EGF or other mitogenic factors, then this should result in activation of downstream signalling processes. In particular, since HB-EGF and many other mitogens activate the ERK pathway (Fang et al., 2001; Lewis et al., 1998) , we reasoned that such an autocrine mechanism would likely result in aberrant ERK regulation. In view of the established role of ERK in promoting cell cycle progression (Brunet et al., 1999; Pages et al., 1993) , it seemed possible that cells transformed by v-Jun might exhibit increased ERK activity, or alternatively, sustain higher levels of active ERK under conditions of mitogen deprivation than persist in quiescent normal CEF.
To evaluate this idea we have investigated the effect of cell transformation by v-Jun on ERK signalling. Unexpectedly, we find that v-Jun-transformed cells exhibit not an increase but a dramatic reduction in the basal level of active ERK, and that ERK becomes refractory to induction by some, although not all, agonists. Biochemical analysis indicates that ERK deactivation is attributable to a combination of defects in upstream signal propagation within the ERK pathway and more rapid inactivation of ERK by MAP kinase phosphatases.
Results

Attenuation of basal ERK activity as a result of cell transformation by v-Jun
To investigate the possible role of ERK signalling in cell cycle deregulation by v-Jun, we first compared the basal levels of active ERK in proliferating control and v-Jun-transformed CEF. Previous studies have shown that CEF express predominantly ERK2 (Sanghera et al., 1992) , and that ERK2 activity can be successfully monitored using antibodies specific for the dualphosphorylated, active form of the enzyme .
Remarkably, although active ERK2 was readily visualised in control cells, little if any could be detected in v-Jun-transformed CEF ( Figure 1A ). This was not due to a reduction in total ERK2 protein as judged by staining with a non-discriminating antibody which recognizes both active and inactive isoforms ( Figure   1A ). Nor was it due to artefactual deactivation of ERK2 during preparation of cell extracts, since the level of active ERK2 detected by confocal immunocytochemistry, which is concentrated in the cell nucleus in growing CEF , was also profoundly reduced in v-Jun CEF ( Figure 1C ). Finally, a similar decrease in ERK2 activity was also detected in immunoprecipitation kinase assays using MBP as a substrate (data not shown).
To further investigate the relationship between v-Jun activity and ERK regulation, we exploited a conditional allele of v-Jun, Dv-JunER, which elicits cell transformation only in the presence of the B-estradiol (Kruse et al., 1997) . As shown in Figure 1B , the level of active ERK2 was unaffected by hormone in control cells expressing the oestrogen receptor hormone binding domain alone (hER CEF), however in the presence of B-oestradiol CEF expressing Dv-JunER exhibited a substantial reduction in the basal level of ERK activity. This was not simply a result of cell . Equal expression of total ERK2 protein was verified using a non-discriminating antibody which recognises both active and inactive ERK2 (lower panel). (B) Levels of total and active ERK2 in CEF expressing hER or the chimeric Dv-JunER oncoprotein cultured in the presence and absence of B-estradiol for 48 h. Total and active ERK2 (arrow) determined by Western blotting as described in (A). (C) Visualisation of active (upper panels) and total (lower panels) ERK2 in proliferating control and v-Jun-transformed CEF by confocal immunocytochemistry using a monoclonal antibody specific for the active, dual-phosphorylated form of ERK transformation per se, since ERK activity was not suppressed in CEF transformed by other oncogenes such as v-Src and c-Myc (data not shown). Taken together, these results indicate that cell transformation by v-Jun specifically suppresses ERK MAP kinase activity.
ERK activity is refractory to induction by serum but remains partially responsive to TPA in v-Jun-transformed CEF A defining characteristic of the ERK pathway is its induction by mitogens such as serum (Lewis et al., 1998) . We therefore asked whether the reduction in basal ERK2 activity induced by v-Jun was associated with a defect in serum inducibility. Exposure of quiescent CEF to 10% serum results in a rapid, transient activation of ERK2 (Figure 2A ), which is maximal around 10 min and which precedes cell cycle re-entry and G1 progression . In comparison, little if any significant induction of ERK2 was observed in v-Jun-transformed CEF in response to serum, even at late times after stimulation ( Figure 2A ).
To confirm that the impairment of serum-induced ERK activity was functionally significant in vivo, we monitored c-Fos proto-oncogene expression, since this is known to be transiently induced via ERK-mediated phosphorylation of ternary complex factors (Treisman, 1994) . Serum stimulation of quiescent control CEF led to a rapid induction of c-Fos protein expression which peaked at 1 h and diminished to control levels by 7 h ( Figure 2B ). In comparison, c-Fos induction was greatly diminished in v-Jun-transformed CEF ( Figure  2B ), indicating that the failure to activate ERK2 attenuates downstream physiological processes regulated by ERK.
We also tested a variety of individual agonists which are thought to activate the ERK pathway via different mechanisms (Marais et al., 1998) for their ability to stimulate ERK signalling in control and v-Juntransformed CEF. As shown in Figure 3A , ERK2 activity was also refractory to induction by epidermal growth factor (EGF) and lysophosphatidic acid (LPA) in v-Jun-transformed cells, however the phorbol ester TPA was able to induce significant levels of ERK2 activity ( Figure 3B , arrow).
v-Jun blocks efficient activation of MEK by serum but not TPA ERK activity is determined by a balance between activatory phosphorylation mediated by the upstream kinases MEK 1 and 2, which are in turn activated by Raf (Lewis et al., 1998) , and deactivation by MAP kinase phosphatases (Keyse, 2000) . The aberrant regulation of ERK2 in v-Jun-transformed CEF therefore seemed likely to be attributable either to a defect in signal propagation at one or more upstream steps in the ERK pathway, an increase in the tonic rate of ERK deactivation, or a combination of both. To distinguish between these alternatives, we first assessed the activation of MEK1/2 by serum and TPA in control and v-Juntransformed CEF.
As shown in Figure 4 , this revealed that serum activated MEK1/2 only weakly in v-Jun CEF compared to control (upper panel), indicating that impaired activation of MEK is likely to contribute to the failure of serum to stimulate ERK efficiently. This was also true for EGF and LPA (data not shown), however TPA was able to activate MEK1/2 equally well in both transformed and normal cells (Figure 4) . It was notable however that the level of active ERK2 induced by TPA in v-Jun CEF was significantly lower than in control cells (Figure 4, lower panel) . This, together with additional observations described in detail below, argue that impaired MEK activation is not the only mechanism through which v-Jun attenuates ERK signalling.
v-Jun interferes with signal propagation between Ras and Raf
To identify the point within the ERK pathway at which v-Jun interferes with MEK activation, we next investigated the levels of Ras-GTP and Raf kinase activities in control and v-Jun-transformed cells exposed to serum and TPA. This analysis revealed that the level of Ras-GTP in control cells, which was undetectable prior to stimulation ( Figure 5 , upper panel), was increased to a similar degree in response to both serum and TPA, and in each case this was associated with a concomitant increase in c-Raf kinase activity ( Figure 5, middle panel) . B-Raf kinase activity was also detectable in these cells, although in contrast to the NIH3T3 mouse cells which we used as a positive control in these assays (data not shown), in CEF B-Raf kinase activity was not stimulated by serum or TPA ( Figure 5, lower panel) . We were unable to detect A-Raf kinase activity using available antibody reagents (EJ Black, unpublished results), however these results suggest that c-Raf, rather than B-Raf, may be the principal activator of MEK and ERK in CEF, at least in response to these agonists. In comparison, the basal level of Ras-GTP was much higher in v-Jun-transformed cells prior to Ras-GTP levels and Raf kinase activity were determined and quantitated by laser densitometry as described previously stimulation, however basal B-Raf kinase activity was reduced rather than increased, whilst exposure to serum elicited only a very marginal increase in the elevated level of Ras-GTP and very weak activation of c-Raf kinase activity ( Figure 5) . Thus, the weak activation of MEK1/2 by serum in v-Jun-transformed cells correlates with failure to activate c-Raf effectively, despite the constitutive presence of high levels of Ras-GTP. In striking contrast, TPA elicited a very large increase in Ras-GTP in v-Jun-transformed cells (to at least 10-fold over normal CEF control) and this was associated with robust activation of c-Raf ( Figure  5) . Thus, the differing capacity of serum and TPA to stimulate MEK1/2 in transformed and control cells is paralleled by differential activation of c-Raf, suggesting that inefficient signal propagation between Ras and c-Raf underlies the failure of serum to stimulate ERK in v-Jun-transformed CEF. It is possible that the reduction in B-Raf kinase activity also contributes to ERK deactivation by v-Jun, however further studies will be required to evaluate this possibility conclusively.
Constitutive Raf signalling activates MEK efficiently in v-Jun-transformed CEF but only partially restores basal ERK activity
If a defect in upstream signal propagation were the sole cause of ERK deactivation in v-Jun-transformed CEF, then introduction of a constitutive Raf signal should rescue the basal level of ERK activity. To test this, we used a dual retroviral infection approach MacLaren et al., 2000) to stably co-express a constitutively active mutant of c-Raf (Raf-Kinase Domain, Raf-KD) in CEF together with v-Jun. Raf-KD was expressed using a neomycin selectable, replication-defective vector (SFCV Raf-KD), which was propagated using a replication competent vector encoding v-Jun (RCAS v-Jun) to provide helper virus functions. Sister cultures infected with appropriate combinations of empty RCAS and SFCV vectors served as controls. Following drug selection uniform expression of both transgenes in the doubly-infected cell cultures was verified by Western blotting ( Figure  6 ).
As shown in Figure 6 , Raf-KD was expressed at similar levels in the presence and absence of v-Jun and was equally active as judged by immunoprecipitation kinase assays (data not shown). Surprisingly however, the downstream effects of Raf-KD on MEK and ERK activity were distinct. In control CEF, expression of Raf-KD increased the basal level of active MEK1/2 and this was associated with a similar increase in the level of active ERK2 (Figure 6 ). In comparison, Raf-KD induced an even larger increase in the basal level of active MEK1/2 in v-Jun-transformed CEF, however this achieved only a partial remediation in the level of active ERK2 (Figure 6 ). Thus, whilst Raf-KD was able to activate MEK efficiently in v-Jun CEF, this was not sufficient to restore the normal basal level of active ERK2.
Increased expression of MKP-1 and MKP-2 in v-Jun-transformed cells
Tonic deactivation by MAP kinase phosphatases is considered to be an important component of ERK regulation (Keyse, 2000) . We therefore considered the possibility that an increase in phosphatase activity might constrain the ability of active MEK1/2 to enhance the basal level of active ERK2 in v-Juntransformed cells. To evaluate this idea, we first investigated the effect of treating cells with sodium pervanadate, a cell permeable inhibitor of MAP kinase phosphatases. As shown in Figure 7A , sodium pervanadate induced a large increase in active ERK to approximately equivalent absolute levels (9.6 and 10.2 arbitrary units respectively) in both cell backgrounds. Since the basal level prior to treatment was much higher in control cells (4.2 to 0.1 arbitrary units respectively), it was evident that the relative fold increase in active ERK2 was greater in v-Juntransformed CEF, a finding which is consistent with more rapid deactivation by a sodium pervanadatesensitive phosphatase(s).
To pursue this idea further we investigated the expression of two dual-specificity MAP kinase phosphatases, MKP-1 and MKP-2, which are known to be capable of deactivating ERK (Keyse, 2000) . We chose to examine these particular phosphatases because MKP-2 mRNA expression was previously shown to be upregulated by v-Jun (Fu et al., 2000) , and we have recently found this is also true of MKP-1 (see Discussion). As shown in Figure 7B , the steady-state level of MKP-1 protein expression was Figure 6 Constitutive Raf signalling stimulates MEK efficiently but only partially restores basal ERK activity in v-Jun-transformed CEF. Cultures of CEF stably infected with RCAS v-Jun and SFCV Raf-KD, or the corresponding empty retrovirus vectors as controls, were analysed for the expression of the retrovirally encoded v-Jun and Raf-KD proteins (upper panels) and for active, phospho-MEK1/2 and active, dual-phosphorylated ERK2 (lower panels). Appropriate non-discriminating antibodies against MEK1/2 and ERK2 were used to verify equivalent protein loading (data not shown) barely detectable by Western blotting in control CEF, however v-Jun-transformed CEF expressed MKP-1 at high levels. This was also true of MKP-2, which although detectable in control cells was also much more abundant in transformed cells. Thus, more rapid deactivation by MKP-1/2 and/or other phosphatases may explain why the Raf-KD signal fails to restore normal basal levels of ERK2 activity in vJun-transformed CEF despite efficient activation of MEK.
Discussion
Previous studies have shown that v-Jun enables cells to sustain cell cycle progression in the absence of exogenous mitogenic signals Clark and Gillespie, 1997) . Since v-Jun upregulates HB-EGF (Fu et al., 1999) , a potential mitogen, we considered the possibility that v-Jun might disturb cell cycle control via an autocrine mechanism. Furthermore, since many mitogens, including HB-EGF (Fang et al., 2001; Lewis et al., 1998) , promote cell cycle progression at least in part via ERK MAP kinase signalling, it seemed possible that autocrine signalling would lead to enhanced or ectopic activation of this pathway.
As we have shown, cell transformation by v-Jun does indeed disturb ERK regulation, although our initial hypothesis that ERK activity might be augmented was not realised. Instead, cells transformed by vJun exhibit a profound decrease in the basal level of ERK, which also becomes refractory to stimulation by serum but remains partially responsive to TPA. These findings raise two important questions; firstly, what is the mechanism of ERK deactivation, and secondly, what is the significance of this phenotype for cell transformation and oncogenesis?
With respect to the first of these, biochemical analysis clearly indicates that v-Jun interferes with ERK pathway regulation both upstream and downstream of ERK itself (Figure 8) . Thus, the failure of serum to stimulate ERK in transformed cells was associated with a significant blunting of both MEK and c-Raf kinase activation, indicating a defect in signal propagation upstream of Raf (Figure 8; 1) . Serum also failed to induce a significant increase in the level of Ras-GTP in v-Jun-transformed cells, although paradoxically this level was already greatly elevated compared to controls. In contrast, induction of ERK activity by TPA was associated with efficient activation of c-Raf and MEK, and tellingly, this was associated with a very large increase in Ras-GTP. These results suggest that transient increases in Ras-GTP may be more significant for c-Raf activation in this system than the absolute steady-state level. They also suggest that the inherent basal rate of Ras-GTP formation is increased as a result of cell transformation by v-Jun, perhaps due to autocrine stimulation by HB-EGF and/ or other factors as previously postulated (Fu et al., 1999) . If this interpretation is correct, then the failure of serum to stimulate c-Raf effectively could paradoxically be due to chronic stimulation of Ras-GTP formation (Figure 8 ).
This latter point may also explain the relative potency of TPA compared to the other ERK agonists we have tested. Both serum and TPA are thought to activate ERK by promoting formation of Ras-GTP (Marais et al., 1998) , however unlike serum, TPA is not thought to act by stimulating guanine nucleotide exchange factor (GEF) activity (Marais et al., 1998) . Instead, it has been proposed that TPA may promote Ras-GTP formation by inhibiting GTPase activating factor (GAP) activity (Marais et al., 1998; Nori et al., 1992) . Although this model is provisional, it is consistent with many of the effects we have observed here. Thus, if v-Jun increased the inherent rate of Ras-GTP formation by stimulating GEF activity via autocrine signalling, then exogenous agonists which operate via this mechanism, such as serum, might be ineffective at further enhancing this elevated rate. In contrast, inhibition of GAP activity by TPA would induce a very large increase in Ras-GTP levels by reducing the rate of GTP hydrolysis against a more rapid rate of GDP -GTP exchange (Marais et al., 1998; Nori et al., 1992) . These predictions closely match what we have observed, however further work will be required to test these ideas explicitly.
Defects in upstream signal propagation are clearly not the only mechanism of ERK deactivation by vJun however, since introduction of a constitutive Raf signal into v-Jun-transformed CEF was not sufficient to restore basal ERK activity to control levels, despite efficient activation of MEK. We believe that this downstream component is attributable to an increase in MAP kinase phosphatase activity for two reasons, although clearly we cannot rigorously exclude the possibility that other mechanisms may also contribute. Firstly, sodium pervanadate, which inhibits MAP kinase phosphatases, restored the basal level of active ERK2 in transformed cells to normal. Secondly, the expression of two candidate ERK phosphatases, MKP-1 and MKP-2, was substantially increased in v-Jun-transformed CEF compared to control. Interestingly, MKP-2 has previously been identified as a vJun target gene using a subtractive cDNA cloning approach (Fu et al., 2000) . In addition, we have recently found MKP-1 mRNA expression to be elevated in v-Jun-transformed CEF through microarray analysis (manuscript in preparation), raising the possibility that this also may be a v-Jun target gene.
Further work will be required to resolve this issue, however it is notable that the MKP-1 gene promoter contains two cyclic AMP-response element (CRE) motifs which could potentially serve as binding sites for v-Jun (Sommer et al., 2000) .
A second important question concerns the potential biological significance of ERK deactivation for cell transformation or oncogenesis by v-Jun. At first glance the deactivation of ERK which we have documented seems counterintuitive, since v-Jun markedly accelerates cell proliferation and ERK signalling is frequently considered to promote cell division. Conversely, ERK deactivation does not appear to be obligatory for cell transformation by v-Jun in vitro, since partial restoration of ERK activity by co-expression of Raf-KD did not lead to phenotypic reversion, at least as judged by cell morphology and accelerated growth rate (EJ Black, unpublished observations). ERK signalling has however also been associated with a variety of other cellular processes whose inhibition could plausibly contribute to oncogenesis in vivo.
For example, it is well established that ERK signalling can promote terminal differentiation in a variety of cell types (Marshall, 1995; Lewis et al., 1998) . One possibility therefore is that deactivation of ERK by v-Jun might block differentiation by interfering with transmission of an inducing signal relayed by this mechanism. Consistent with this idea, v-Jun is a potent inhibitor of differentiation in vitro (Su et al., 1991) , although the underlying mechanism has not been established. Alternatively, ERK inhibition might be significant in the context of oncogene cooperation. Multiple genetic changes are required to generate fully malignant tumour cells, and in some cases oncogenes are thought to cooperate by suppressing potentially deleterious consequences of cell transformation by single genetic lesions. One wellcharacterized example is provided by the growth arrest or premature senescence phenotype induced by activated Ras and Raf oncogenes (Sewing et al., 1997; Woods et al., 1997; Zhu et al., 1998) . The growth-inhibitory effects of Ras and Raf are thought to be mediated through chronic, sustained ERK MAP kinase activation which results in accumulation of the p21 CIP1 CDK inhibitor (Sewing et al., 1997; Woods et al., 1997; Zhu et al., 1998) . Recent evidence has shown that ERK-mediated p21 CIP1 accumulation and thus growth arrest can be suppressed by increased levels of Rho signalling (Sahai et al., 2001; , however it is reasonable to predict that chronic inhibition of the ERK pathway itself would have a similar effect. Deactivation of ERK by v-Jun might therefore cooperate with Ras activation or other genetic lesion(s) which accumulate during the complex process of oncogenic conversion in vivo. Further work, including the identification and characterization of the avian homologue of p21 CIP1, will be needed to test these hypotheses and fully understand the consequences of this phenotype for cell physiology and oncogenesis. 
